(Q96352766)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

3 references

13 July 2022

22 October 2022

24 October 2022

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

1 reference

1 reference

inferred from abstract

author name string

Siyu Xiu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Alexej Dick

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Han Ju

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Sako Mirzaie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Fatemeh Abdi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Simon Cocklin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Peng Zhan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

Xinyong Liu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

publication date

15 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

Journal of Medicinal Chemistry

17 June 2020

12 November 2020

3 references

13 July 2022

22 October 2022

24 October 2022

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32539378%20AND%20SRC:MED&resulttype=core&format=json

17 June 2020

13 July 2022

22 October 2022

24 October 2022

Recent discovery and development of inhibitors targeting coronaviruses

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Severe acute respiratory syndrome (SARS): a year in review.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A pneumonia outbreak associated with a new coronavirus of probable bat origin

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Drug targets for corona virus: A systematic review

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Mouse hepatitis virus type 2 enters cells through a clathrin-mediated endocytic pathway independent of Eps15

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A decade after SARS: strategies for controlling emerging coronaviruses

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A new coronavirus associated with human respiratory disease in China

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Pathology and pathogenesis of severe acute respiratory syndrome

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Antibody Therapy for the Control of Viral Diseases: An Update

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Monoclonal antibodies for prophylaxis and therapy of infectious diseases

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Monoclonal antibodies against viruses and bacteria: a survey of patents

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A human monoclonal antibody blocking SARS-CoV-2 infection

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Therapeutic potential of small molecules and engineered proteins

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

What are the drugs of the future?

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Angiotensin-converting enzyme 2: cardioprotective player in the renin-angiotensin system?

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Using Peptidomimetics and Constrained Peptides as Valuable Tools for Inhibiting Protein–Protein Interactions

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Novel peptide inhibitors of angiotensin-converting enzyme 2.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Novel polymeric inhibitors of HCoV-NL63.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

HTCC: Broad Range Inhibitor of Coronavirus Entry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Angiotensin-converting enzyme 2 protects from severe acute lung failure.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structures and polymorphic interactions of two heptad-repeat regions of the SARS virus S2 protein

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Inhibition of human coronavirus NL63 infection at early stages of the replication cycle

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A small-molecule fusion inhibitor of influenza virus is orally active in mice

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Caught in the act: the crystal structure of cleaved cathepsin L bound to the active site of Cathepsin L

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Teicoplanin potently blocks the cell entry of 2019-nCoV

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Protease inhibitors targeting coronavirus and filovirus entry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Perspectives for repurposing drugs for the coronavirus disease 2019

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Phenotypic vs. target-based drug discovery for first-in-class medicines

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Overview of Recent Strategic Advances in Medicinal Chemistry

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Prospects for a MERS-CoV spike vaccine

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol

18 May 2021

1 reference

https://api.crossref.org/works/10.1021/ACS.JMEDCHEM.0C00502